A multicenter study of Sandoz' somatostatin analog octreotide for the treatment of AIDS-related diarrhea has produced mixed results, according to a report in AIDS Clinical Care.
Around 130 AIDS patients were given octreotide or placebo by subcutaneous injection three times a day. After 21 days, 46% of the octreotide group had achieved the goal of a 30% decrease in stool weight, compared to 36% of the placebo group. The two groups had similar reductions in bowel-movement frequency, according to the report.
Although patients with idiopathic diarrhea (diarrhea lasting more than 13 weeks, body weight under 60 kg, or CD4 levels below 50) showed a better response to the treatment, the differences between the two groups remained insignificant. During a subsequent open-label phase, the octreotide dose was boosted, and after eight weeks, both stool weight and bowel-movement frequency decreased significantly. The researchers note that even though the results of the controlled study were disappointing, the open-label results indicate that longer-term treatment at higher doses could be effective.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze